ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Schmidt Approve NCAB Authorizations

February 18, 1977

Children’s Oncology Group Study Shows Improved Care For Childhood Brain Tumors

October 31, 2008

Army Hopes To Fund “Middle-Risk, high Payoff” Research With Breast Cancer money. Travis Says

February 19, 1993

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004

The March: Research Task Force Calls For $10 Billion For NCI In 5 Years

October 23, 1998

In Brief: Peter Fischinger Names NCI Deputy Director; ACR Moves Headquarters To Washington Area

November 8, 1985